Wang Liang, Han Minglei, Zhao Junyang, Wu Changhua, Wang Zhongqi, Li Jing, Song Dan, Wang Changfeng, Yang Yang, Guo Lei
Department of Interventional Radiology and hemangioma.
Department of Ophthalmology, Qilu Children's Hospital of Shandong University.
Medicine (Baltimore). 2018 Oct;97(42):e12676. doi: 10.1097/MD.0000000000012676.
Intra-arterial chemotherapy (IAC) has become an essential technique for the management of advanced intraocular retinoblastoma (RB). In this study, the aim of this article is to describe the clinical results and the short-term complications of IAC performed in our hospital.We retrospectively analyzed patients with newly diagnosed unilateral advanced intraocular (group D or E) RB undergoing IAC from October 2016 to December 2017 in our hospital. We recorded the data including age, gender, cycles of IAC, pathway of arteries approached (ophthalmic artery or middle meningeal artery), ocular and systematic complications, globe salvage.Sixty-one patients underwent IAC performing 189 procedures with a median of 3.1 sessions per eye (range, 1-5 sessions). The overall globe salvage rate is 78.7% (Group D (84.2%), and Group E (69.6%) and followed-up. Short-term ocular complications include eyelid edema (15 cases), ptosis (5 cases), forehead congestion (3 cases), retina hemorrhage (5 cases), choroid atrophy (2 cases), phthisis bulbi (1 case), bradycardia and hypotension during the procedure (7cases), myelosuppressions (6 cases), and nausea and vomiting (5cases).IAC is safe and effective for the treatment of unilateral advanced intraocular RB with a very low complication rate.
动脉内化疗（IAC）已成为治疗晚期眼内视网膜母细胞瘤（RB）的一项重要技术。在本研究中，本文旨在描述我院进行的IAC的临床结果和短期并发症。我们回顾性分析了2016年10月至2017年12月在我院接受IAC治疗的新诊断为单侧晚期眼内（D组或E组）RB的患者。我们记录了包括年龄、性别、IAC周期、所接近的动脉途径（眼动脉或脑膜中动脉）、眼部和全身并发症、眼球挽救情况等数据。61例患者接受了IAC治疗，共进行了189次操作，每只眼的中位疗程为3.1次（范围为1 - 5次）。总体眼球挽救率为78.7%（D组为84.2%，E组为69.6%）并进行了随访。短期眼部并发症包括眼睑水肿（15例）、上睑下垂（5例）、前额充血（3例）、视网膜出血（5例）、脉络膜萎缩（2例）、眼球痨（1例）、术中心动过缓和低血压（7例）、骨髓抑制（6例）以及恶心和呕吐（5例）。IAC治疗单侧晚期眼内RB安全有效，并发症发生率极低。
